Nuevos tratamientos contra el cáncer

Reglas del Foro
Este espacio únicamente pretende ser informativo, divulgativo y de opinión; y en ningún caso sustituir al criterio médico cualificado, ni sugerir o proporcionar terapias de ningún tipo.
firehand
Especulador Listillo
Mensajes: 317
Registrado: 02 Sep 2012 05:29

Nuevos tratamientos contra el cáncer

Mensajepor firehand » 04 Jun 2013 07:44

Conocidos como inhibidores de PD-1 y de PD-L1, los nuevos fármacos representan un avance conceptual en el tratamiento del cáncer. Si la mayoría de terapias utilizadas hasta ahora –y que se seguirán utilizando- se basan en atacar directamente las células tumorales, la nueva estrategia se basa en habilitar el sistema inmunitario para que sea él quien ataque estas células.

Según los resultados presentados por Ribas, el 52% de un grupo de pacientes con melanoma avanzado tratados con lambrolizumab –un inhibidor de PD-1- han respondido al tratamiento. De ellos, uno de cada cinco ha tenido una respuesta completa –es decir, ha desaparecido todo rastro de cáncer de su organismo.

Un estudio similar dirigido desde el hospital Memorial Sloan-Kettering de Nueva York, también presentado en Chicago, ha obtenido resultados similares. El 47% de un grupo de pacientes con melanoma avanzado ha respondido a la inmunoterapia y, de ellos, casi nueve de cada diez han tenido una reducción del tumor superior al 80% en menos de tres meses.

Fuente: http://www.lavanguardia.com/ciencia/201 ... z2VBSzHJtO

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 10:51

Que buenas noticias!

Tambien estoy viendo el sistema de la quimiosaturacion que se trata de llevar un pequeño vehiculo al tumor y descargar ahi una cantidad enorme de quimioterapia que no circulo por el resto del organismo solo en el tumor, de momento se esta experimentando en cancer de higado.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 19:32

This weekend a slate of biopharma companies will be presenting new data at ASCO, underscoring the big new role that immunotherapy drugs will be playing in the fight against cancer. In part, that's because of the success of Yervoy, which sells for $40,000 a month. Now Bristol-Myers Squibb ($BMY), Merck ($MRK) and others believe they have a key to further advances in a variety of cancers. And that's raising some big questions about the impact these drugs will have in a market that is feeling the impact of six-figure oncology treatments.

Bristol-Myers Squibb is one of the leaders in this movement. Two years after it gained an approval for Yervoy, the drug developer is back with a closely watched combo that adds nivolumab to the mix. The drug targets the PD-1 cloaking device, opening up a fresh T-cell attack on a variety of solid tumors. The FDA has put it on the agency's fast track for melanoma, lung and kidney cancer.

These new therapies will likely add considerably to the cost of care. As they rescue a growing number of patients from an early death, they'll also become chronic disease therapies that could be needed for years to come. A Nature article picks up on the cost trend, noting that cancer drug costs are rising at 15% a year, twice the rate of overall healthcare inflation. That's likely to make these drugs a lightning rod for private and public payers looking to contain the cost of healthcare in the U.S.

Read more: ASCO presentations portend future shock of immunotherapy drug prices - FierceBiotech http://www.fiercebiotech.com/story/asco ... z2VGmpTIci
Subscribe at FierceBiotech

"Cancer is a very complicated and expensive disease," Scott Ramsey, a healthcare economist at the Fred Hutchinson Cancer Research Center in Seattle, Washington, tells Nature. "But now it's turning into a chronic disease, and we're talking about years of maintenance therapy with drugs that cost $10,000 a month."

Read more: ASCO presentations portend future shock of immunotherapy drug prices - FierceBiotech http://www.fiercebiotech.com/story/asco ... z2VGmb0mja
Subscribe at FierceBiotech


Es caro si... tendran que reducir los precios una vez que amorticen el coste de la investigacion y vayan saliendo competidores o las patentes caduquen.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 19:36

Oncology is the most crowded area of drug research. So the shorter development cycle helps limit companies' risk of chasing the same or very similar targets as a bevy of other companies, wagering on their program to come out on top. Novartis might have the frontrunner with LDK378, but it is one of no fewer than four experimental compounds against ALK in lung cancer. These drugs home in on misfit proteins in an ALK-positive subgroup that represents as little as 3% of the NSCLC population.

The FDA is opening the inside track to more genetic therapies in response to overwhelming patient need, as the efficacy of the first wave of gene-targeting drugs fades after clever cancers adapt and find new pathways to grow out of control. Roche ($RHHBY) and other companies also face patent expirees to existing drugs, and the Swiss drugmaker has mounted an effort to make one of its best drugs, Rituxan, even greater with a glycoengineered successor called GA101.

Targeted or not, none of these drugs is a silver bullet, and patients must still endure side effects. Yet there's hope for some cancers to become manageable chronic illnesses as opposed to death sentences.


Fuente: http://www.fiercebiotech.com/special-re ... z2VGo1y3Gg
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 19:39

Ibrutinib has sparked a frenzy of activity in the clinical and investment worlds with promising evidence of efficacy in a lineup of B-cell cancers. The blockbuster prospects of the Bruton's tyrosine kinase (BTK) inhibitor have driven the market value of its developer, Pharmacyclics ($PCYC), to more than $5 billion, the highest among clinical-stage companies in the oncology arena, and stamped company CEO and Chairman Bob Duggan's ticket into the billionaire's club.

As one physician described ibrutinib to a Forbes scribe recently, the compound could become the Gleevec of B-cell cancers such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. Now in Phase III studies, ibrutinib has shown impressive response rates and progression-stealing results in midstage tests. In a Phase Ib/II study in CLL patients, for instance, cancer progression halted in an estimated 96% of patients without prior treatment and 75% of those with high-risk cases at up to 26 months after they started to take ibrutinib.
Johnson & Johnson ($JNJ) wants to add the compound to its growing roster of cancer therapies, and the pharma giant and Pharmacyclics have raced ahead with 5 late-stage clinical trials for the experimental drug through their collaboration that began in December 2011. The partners have already found a supportive audience with the FDA, which has granted three "Breakthrough Therapy" designations for the compound for use in separate pools of cancer patients.

With the first submission for FDA approval expected in the third quarter of 2013, Pharmacyclics and J&J could win a quick stamp from the agency and have ibrutinib cleared for the U.S. market before the end of the calendar year. The pace of the agency's action on the application will speak volumes about the value of "Breakthrough" status. If approved for CLL and other uses, analysts estimate that ibrutinib could become one of the biggest moneymakers in oncology with up to $5 billion in annual sales.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 19:46

Idelalisib targets a subset of PI3K proteins that is known to accelerate the development of cancer, the kind of clear biologic pathway the FDA enjoys. As a result, it's in direct competition with IPI-145, a PI3K delta and gamma inhibitor in development at Infinity Pharmaceuticals ($INFI), which has been winning some enthusiastic supporters with evidence of possibly greater activity and lower liver toxicity. But while Infinity has been focusing on restructuring the company around IPI-145, which is now delivering Phase I data, Gilead has been ramping up its late-stage clinical campaign, putting its drug well in the lead. And now Infinity may be forced to settle for next-gen drug status as it watches Gilead hustle ahead.

It certainly doesn't lack for attention. ASCO President Sandra Swain called the recent results "pretty incredible," while Dana-Farber's Jennifer Brown enthused: "Drugs like idelalisib are probably going to change the landscape of the disease in the next few years."
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 04 Jun 2013 19:49

En nanoparticulas:

PSMA-targeted nanoparticle containing docetaxel

While easily the least proven candidate in this report, BIND-014 has shown early promise in combatting a range of solid tumors in Phase I trials, and Bind Therapeutics plans to prove the mettle of its lead candidate in three Phase II trials slated for this year in lung, prostate and bladder cancers.

Cambridge, MA-based Bind highlighted the Phase I data on 014, which encapsulates the chemo drug docetaxel in a nanoparticle, in an oral presentation at the American Association for Cancer Research. Getting the spotlight at AACR is no small deal. In 28 cancer patients who had already received a battery of treatments, Bind's drug shrank or stabilized tumors in 9 patients, including a complete response in a patient with cervical cancer as well as partial responses in patients with non-small cell lung, prostate and ampullary tumors.

Bind has a long way to go with this program. Yet based on early work with its Accurin nanotechnology platform, the company has landed a troika of major corporate partnerships this year on other assets with Amgen ($AMGN), Pfizer ($PFE) and AstraZeneca ($AZN). Those deals improve the odds of a success from Bind's technology, which came from labs of MIT inventor Bob Langer and his colleagues.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 03 Ago 2013 18:52

A DNA cancer vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals caused tumor cell death and increased the rate of survival in animal studies. Using the company's adaptive electroporation delivery technology, the hTERT DNA vaccine broke the immune system's tolerance to its self-antigens and induced T cells with a tumor-killing function. High levels of human telomerase reverse transcriptase, also known as hTERT, are detected in over 85% of human cancers.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 26 Ago 2013 20:00

Amplimmune's claim to fame rests on its IMT-C platform, which AstraZeneca describes much like the clinical-stage PD-1 drugs that were at the center of ASCO's spotlight last summer. The technology revs up the immune system so it can overwhelm cancer cells' cloaking mechanism that keeps the cancer hidden from the immune system.

"MedImmune's focus on harnessing the power of the patient's own immune system to fight cancer will be complemented by Amplimmune's innovative work in this area. It will allow us to strengthen our arsenal of potential cancer therapies"
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!

Avatar de Usuario
Dalamar
Site Admin
Mensajes: 8966
Registrado: 09 May 2012 01:38

Re: Nuevos tratamientos contra el cáncer

Mensajepor Dalamar » 30 Sep 2013 21:25

"There is no discussion, this is really working," Soria told reporters at the European Cancer Congress in Amsterdam, according to a Bloomberg report. "This is the first targeted agent showing more activity in smoking patients than in never smokers." And he speculated that the larger number of genetic mutations present in the lung cancer that afflicts smokers helped explain the higher rate of success for a drug that can unleash an immune system assault.

MPDL3280A is one of three immunotherapy drugs that have transfixed the oncology field. At ASCO last summer investigators zeroed in on very promising early data highlighting the extraordinary promise of these treatments in fighting cancer. Bristol-Myers Squibb ($BMY) took the initial lead in the field with a strong 40% response rate found in a melanoma study of a Yervoy/nivolumab combo, offering a look at the potential of a PD-1 treatment. Then Merck ($MRK), which has been struggling to find something positive to say about its hapless research efforts, stepped up with stellar data for MK-3475, now the star program in its pipeline.

PD-1 and PD-L1 are the two partners--a kind of lock-and-key mechanism--that play an important role in the immune system, camouflaging cancer cells while fighting invaders like viruses and bacteria. By targeting either end of the lock and key, a drug can reveal the cancer in such a way that the immune system fields an army of T cells to fight it off. Combining these immunotherapies with other targeted therapies is seen as a major new step in oncology with the potential for remarkable improvements for many cancer patients.

The market potential for these drugs is enormous--Citigroup analysts estimated the field could be worth $35 billion--which no one is ignoring.
¿Te ha gustado este hilo? Compartelo en las redes sociales para que se sume mas gente a la conversacion!


Volver a “Salud”

cron

Ingresar